<DOC>
	<DOCNO>NCT00880789</DOCNO>
	<brief_summary>With study , want see use kind white blood cell call T cell prevent treat AdV CMV infection . We grow T cell cord blood patient transplant . These cell train attack adenovirus/CMV-infected cell call Adenoviral/CMV-specific cytotoxic ( killer ) T-cells `` AdV/CMV-CTL . '' We would plan give patient one dose AdV/CMV-CTL time 30 day transplant . We use T cell make way blood donor prevent infection patient get bone marrow blood stem cell transplant first time make cord blood .</brief_summary>
	<brief_title>Safety , Toxicity MTD One Intravenous IV Injection Donor CTLs Specific CMV Adenovirus</brief_title>
	<detailed_description>We plan grow T cell cord blood laboratory special way , see help prevent treat infection transplant patient virus . This therapy specially trained T cell ( call CTLs ) activity virus cell make donor blood give patient receive bone marrow blood stem cell transplant . We want find use CTLs make cord blood prevent treat viral infection patient 's immunity weak receiving cord blood transplant . These cell call `` CMV/AdV specific CTLs '' attack two virus . The doctor already find cord blood unit suitable patient 's transplant . If patient agree study take 5-10 ml ( 1-2 teaspoon ) cord blood unit transplant . We take much cord blood available specially freeze small fraction cord blood unit . We use cord blood grow T cell lab . From blood first grow special type cell call dendritic cell put specially produce human virus ( adenovirus ) carry CMVpp65 gene dendritic cell . The dendritic cell irradiate grow use stimulate T cell . This stimulation train T cell kill cell CMV adenovirus surface . We grow large number AdV/CMV-specific CTLs stimulation EBV infect B cell ( make cord blood infect EBV laboratory ) . We also put special virus B cell AdV/CMV . Again , B cell treat radiation grow . Once make enough T cell test make sure kill cell infect Adenovirus CMV . To make sure cell wo n't attack patient 's healthy tissue , test cell blood cell grow laboratory . These used check see AdV/CMV CTL attack . Alternatively , may take blood first degree relative take small piece skin patient grow skin cell , also use check AdV/CMV CTL attack . The skin biopsy do time another procedure bone marrow biopsy . The cord donor 's AdV/CMV CTL cell thaw injected IV line period 10 minutes.Patients may premedicated Benadryl Tylenol . If patient agree he/she well enough , one dose CTL give day 30 follow transplant . If patient AdV/CMV infection give antiviral medication study monitor patient closely check AdV/CMV infection . If patient AdV/CMV infection CTL infusion may also treat antiviral medication study . We monitor patient closely AdV/CMV infection collect blood possibly urine stool test AdV/CMV .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>INCLUSION CRITERIA : Inclusion criterion time Procurement : Patient malignant nonmalignant disease candidate transplant . Patients must single CB unit match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigens . The unit must cryopreserved two fraction , minimum 2.5x10^7 total nucleated cell per kg prethaw fraction use primary transplant . The remain fraction use generate CTLs give day 30 beyond describe . Inclusion criterion time CTL infusion : Recipients single cord blood unit fractionate 2 fraction ( i.e . HLA match mismatch unrelated donor ) transplant risk CMV/Adenoviral disease reactivation . Lansky/Karnofsky score 60 great Absolute neutrophil count ( ANC ) great 500/ul . No evidence GVHD &gt; Grade II time enrollment . Life expectancy &gt; 30 day Absence severe renal disease ( Creatinine &gt; x 3 normal age ) Absence severe hepatic disease . Direct bilirubin must less 3 mg/dl AST le 5x upper limit normal Patient must least 30 day post transplant eligible receive CTL Written inform consent and/or sign assent line patient , parent guardian . Patient Fi02 &gt; 60 % EXCLUSION CRITERIA : Exclusion criterion time Procurement : Pregnant Lactating Patients active central nervous system disease Patients Karnofsky performance status &lt; 70 % Patients grade 3 4 primary myelofibrosis Patients suitable related donor Exclusion criterion time CTL infusion : Pregnant lactate Unable wean steroid 0.5 mg/kg/day less prednisone . Patients uncontrolled infection ( except CMV and/or adenovirus and/or EBVemia absence PTLD ) . For bacterial infection , patient must receive definitive therapy sign progress infection 72 hour prior enrollment . For fungal infection patient must receive definitive systemic antifungal therapy sign progress infection 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Patients less 50 % donor chimerism either peripheral blood bone marrow patient relapse original disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Cord Blood Transplant</keyword>
	<keyword>cytomegalovirus</keyword>
	<keyword>CMV</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>ADV</keyword>
</DOC>